Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Live Birth Rate in Women with Recurrent Pregnancy Loss after In Vitro Fertilization with Concomitant Intravenous Immunoglobulin and Prednisone

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Impella to Treat Acute Myocardial Infarct-Related Cardiogenic Shock

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Quantitative MR Markers in Non-Myelopathic Spinal Cord Compression: A Narrative Review

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. Estimating Renal Function Following Lung Transplantation

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Feelings of guilt and loss of control dominate in stress and depression inventories from women with recurrent pregnancy loss

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Pregnancy loss and risk of multiple sclerosis and autoimmune neurological disorder: A nationwide cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. The untapped potential of reproductive history in cardiovascular disease

    Publikation: Bidrag til tidsskriftLederForskningpeer review

Vis graf over relationer

Pregnancy loss after in vitro fertilization (IVF) is at least as common as after spontaneous conception. Recurrent pregnancy loss (RPL) may often have an immunological background, and it is therefore relevant to test immune-based interventions in these patients. The objective was to investigate the effect of immunotherapy with intravenous immunoglobulin (IvIg) and prednisone (PRS) as concomitant therapy to IVF in women with RPL after earlier IVF treatments. In a cohort study conducted at The Danish RPL Clinic, 41 women with three or more consecutive pregnancy losses after IVF underwent at least one further IVF cycle with concomitant immunotherapy from 2012 to 2017. The immunotherapy with IvIg and PRS was given before embryo transfer and repeatedly in the first trimester when pregnancy was achieved. Fourteen women (34.2%) achieved a live birth after the first embryo transfer with immunotherapy, and a total of 32/41 (78%) achieved a live birth after up to 4 embryo transfers. Baseline characteristics and the presence of autoantibodies were not significantly different among women achieving live birth or not. The observed 34% birth rate in women with RPL after IVF receiving immunotherapy appears higher than the expected 16-19% birth rate without immunotherapy and is similar to findings in a previous cohort from our clinic. Concomitant immunotherapy as described may be a promising intervention for women with RPL after IVF; however, the effect must be tested in a randomized controlled trial.

OriginalsprogEngelsk
Artikelnummerjcm11071894
TidsskriftJournal of Clinical Medicine
Vol/bind11
Udgave nummer7
Sider (fra-til)1-10
Antal sider10
ISSN2077-0383
DOI
StatusUdgivet - 29 mar. 2022

ID: 76294656